Targeted Protein Degradation (TPD) Market (2026-2036)

According to Arvinas' 2025 annual report, the company's ARV-471 (vepdegetamide), a PROTAC degrader targeting estrogen receptor, demonstrated a 37.1% clinical benefit rate in heavily pretreated ER-positive HER2-negative breast cancer in its Phase 2 VERITAC-2 trial, and this program along with ARV-766 for prostate cancer represent the most clinically advanced PROTAC therapeutics globally, providing the commercial proof-of-concept that is attracting billions of dollars of pharmaceutical industry investment into the TPD field.

Targeted protein degradation is a therapeutic modality that redirects the cell's own protein disposal machinery, specifically the ubiquitin-proteasome system or the autophagy-lysosome pathway, to selectively degrade disease-causing proteins. Unlike conventional small molecule inhibitors, which bind to the active site of a target protein and block its function, a degrader molecule acts as a chemical bridge connecting the target protein to an E3 ubiquitin ligase enzyme, which tags the target with ubiquitin chains that mark it for destruction by the proteasome. This event-driven pharmacology has two profound advantages over occupancy-based inhibition: first, the degrader molecule is released intact after each catalytic degradation event and can recruit additional target molecules in a substoichiometric manner, meaning very small drug doses can eliminate large quantities of disease protein; second, degradation eliminates all protein functions, including scaffolding and protein-protein interaction functions that cannot be inhibited by blocking the active site, potentially making previously undruggable proteins tractable.

The market is growing rapidly because the pharmaceutical industry has recognized TPD as the most significant new drug modality since monoclonal antibodies, capable of addressing the estimated 80 to 90% of disease-relevant proteins that are currently undruggable by conventional small molecules because they lack well-defined binding pockets suitable for inhibitor design. According to a 2024 analysis published in Nature Reviews Drug Discovery, the number of PROTAC-type molecules in active clinical development exceeded 30 programs across oncology, immunology, and other therapeutic areas, more than doubling from 14 programs in 2021. The publication of Phase 2 clinical data from Arvinas' vepdegetamide PROTAC in breast cancer, which demonstrated clinically meaningful objective responses in patients who had failed multiple prior lines of therapy including CDK4/6 inhibitors and fulvestrant, represents the most important clinical validation milestone in the field's history.

The broader pharmaceutical industry's recognition of TPD is reflected in the scale of investment. According to Evaluate Pharma's 2025 drug development report, TPD-focused companies collectively raised over USD 2 billion in venture capital and public equity financing in 2024, with major pharmaceutical companies including Bristol Myers Squibb, Pfizer, Merck, Novartis, and Sanofi all entering the field through licensing deals, acquisitions, or internal programs. Bristol Myers Squibb's acquisition of Celgene in 2019 brought the molecular glue immunomodulatory drug lenalidomide, already a blockbuster cancer treatment, into its portfolio and established BMS as a leading molecular glue developer. The company disclosed in its 2025 R&D pipeline communications that molecular glue and PROTAC programs represent one of its highest-priority internal development areas.